title: Survivin isoforms and clinicopathological characteristics in colorectal adenocarcinomas using real-time qPCR.
abstract: OBJECTIVE
  To investigate three isoforms of survivin in colorectal adenocarcinomas.
  
  
  METHODS
  We used the LightCycler Technology (Roche), along with a common forward primer and reverse primers specific for the splice variants and two common hybridization probes labeled with fluorescein and LightCycler-Red fluorophore (LC-Red 640). Real time quantitative polymerase chain reaction (PCR) was performed on cDNAs from 52 tumor specimens from colorectal cancer patients and 10 unrelated normal colorectal tissues. In the patients group, carcinoembryonic antigen (CEA) and CA19-9 tumor markers were also measured immunochemically.
  
  
  RESULTS
  Wild type survivin mRNA isoform was expressed in 48% of the 52 tumor samples, survivin-2b in 38% and survivin-ΔΕx3 in 29%, while no expression was found in normal tissues. The mRNA expression of wild type survivin presented a significant correlation with the expression of the ratio of survivin-2b, survivin-ΔΕx3, survivin-2b/wild type survivin and survivin-ΔΕx3/wild type survivin (P < 0.001). The mRNA expression of wild-survivin and survivin-ΔΕx3 was related with tumor size and invasion (P = 0.006 and P < 0.005, respectively). A significant difference was found between survivin-2b and morphologic cancer type. Also, the ratio of survivin-ΔEx3/wild-survivin was significantly associated with prognosis. No association was observed between the three isoforms and grade, metastasis, Dukes stage and gender. The three isoforms were not correlated with CEA and CA19-9.
  
  
  CONCLUSIONS
  Survivin isoforms may play a role in cell apoptosis and their quantification could provide information about clinical management of patients suffering from colorectal cancer.
authors.affiliation: Department of Clinical Biochemistry, Attikon University Hospital, Athens 12462, Greece. anastasiada@hotmail.com
authors.forename: Anastasia
authors.initials: A
authors.lastname: Pavlidou
authors.forename: Maria
authors.initials: M
authors.lastname: Dalamaga
authors.forename: Christos
authors.initials: C
authors.lastname: Kroupis
authors.forename: George
authors.initials: G
authors.lastname: Konstantoudakis
authors.forename: Maria
authors.initials: M
authors.lastname: Belimezi
authors.forename: George
authors.initials: G
authors.lastname: Athanasas
authors.forename: Kleanthi
authors.initials: K
authors.lastname: Dimas
mesh_terms: D000230:Adenocarcinoma / Q000235:genetics* / Q000276:immunology / Q000401:mortality / Q000473:pathology; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000704:Analysis of Variance; D017209:Apoptosis; D018395:CA-19-9 Antigen / Q000032:analysis; D002272:Carcinoembryonic Antigen / Q000032:analysis; D016022:Case-Control Studies; D016009:Chi-Square Distribution; D015179:Colorectal Neoplasms / Q000235:genetics* / Q000276:immunology / Q000401:mortality / Q000473:pathology; D005260:Female; D006115:Greece; D006801:Humans; D007150:Immunohistochemistry; D051034:Inhibitor of Apoptosis Proteins / Q000235:genetics*; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D009367:Neoplasm Staging; D016133:Polymerase Chain Reaction; D011379:Prognosis; D020033:Protein Isoforms; D012333:RNA, Messenger / Q000032:analysis; D000077022:Survivin; D047368:Tumor Burden
chemical_list: C107489:BIRC5 protein, human; D018395:CA-19-9 Antigen; D002272:Carcinoembryonic Antigen; D051034:Inhibitor of Apoptosis Proteins; D020033:Protein Isoforms; D012333:RNA, Messenger; D000077022:Survivin